GET TO KNOW OUR EXPERIENCED MANAGEMENT TEAM

OUR LEADERSHIP TEAM

ZALÁN
PÉTERFI

MD, PhD
Chairman of the Board, Managing Director
ZALÁN’S ROLE IS TO BUILD THE VRG Tx TEAM AND TO OVERSEE THE COMPANY’S OPERATIONS

Zalán is a Harvard-trained scientist, ex-Mckinsey consultant with extensive experience in the pharma and biotech industry. He is passionate about and experienced in topics where both scientific/medical expertise and management/business excellence are essential to drive maximum impact. He is a life-science focused leader with the ability to recruit, train, and manage high-performing teams demonstrated by 10+ years of leadership in academic and business settings.

SÁNDOR
FARKAS

MD, PhD
Director of Research and Intellectual Property
SÁNDOR’S ROLE IS TO ENSURE THAT SCIENCE IS IN LINE WITH INDUSTRIAL STANDARDS AND HE IS RESPONSIBLE FOR IP STRATEGY AND EXECUTION.

Sándor is a non-clinical pharmacologist and drug development scientist, with over 33 years of experience in the pharma Industry. He worked as a research scientist at the University of Tokyo, Japan. His special areas of expertise include all phases of early drug development from target identification to non-clinical support of clinical development. He provided training and education in the discipline of pharmaceutical medicine. Author of 39 scientific publications and inventor of 23 patent applications involving 6 drug candidates that reached clinical development.

ZOLTÁN
URBÁNYI

PHD
Director of Biologics Development
Zoltán is responsible for biologics development and especially for the CMC (chemistry, manufacturing, and controls).

Zoltán is a seasoned life science leader with 35+ years of experience in pharmaceutical R&D including 15+ years in the development of biologics at Gedeon Richter. His career encompasses extensive experience in drug research, management, and project leadership. He has a special expertise in the analytics and characterization of biopharmaceuticals, and he is experienced in the management of the whole preclinical R&D process as well. He participated in several R&D projects including ones with assets that are currently marketed or in clinical phase.

TAMÁS
KITKA

PHD
Director of Portfolio and Innovation
TAMÁS IS RESPONSIBLE FOR PORTFOLIO STRUCTURE AND PROGRESS AND FOR SCIENTIFIC STRATEGY AND IMPLEMENTATION.

He is a pharmaceutical R&D expert and holds a PhD in Neurobiology. He has 10+ years of experience in the pharmaceutical industry in various positions: researcher/developer, project manager, research team leader, and business development manager. His experience embraces the full non-clinical R&D process in various types of projects (small molecules, biologics, etc.). He participated several projects in either research or development phase that have later been tested in clinical trials.

MÁRTON
MEGYERI

PhD, MBA
VP of Scientific Operations
MÁRTON IS RESPONSIBLE FOR SCIENTIFIC STAFF MANAGEMENT AS WELL AS CHEMISTRY MANUFACTURING AND CONTROLS (CMC) AND REGULATORY AFFAIRS.

Márton is a Weizmann Institute-trained scientist with a primary degree in bioengineering and a PhD in structural biochemistry. He has 15+ years of academic track record and 10+ years of industrial biotechnology R&D experience with Chemistry, Manufacturing, and Controls (CMC) and Regulatory expertise. He possesses hands-on experience in biologics drug substance and drug product development, along with supporting analytics. Márton has participated in several BPD Type 2 meetings with the FDA and has driven successful IND submissions.

TAMÁS
CSIKAI

Chief Financial Officer
TAMÁS IS RESPONSIBLE FOR FINANCIAL AND OPERATIONAL STABILITY AS WELL AS INVESTOR RELATIONS.

Tamás holds a degree in finance and accounting from the Corvinus University of Budapest and has 10+ years of finance, strategy and operations experience. He started his career at KBC Group as a corporate finance analyst. Later he was a management consultant at McKinsey and Company. Recently, he was a subsidiary finance and operations director at OTP Group. He has previously laid the strategy and successfully built a new venture at OTP Group from scratch via a mix of organic and inorganic (M&A) activities.

Our website uses cookies to provide your browsing experience and relavent informations. Before continuing to use our website, you agree & accept of our Cookie Policy & Privacy